CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
The US government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for 100 million doses of COVID-19 vaccines covering 50 million people and underwrite the drug makers’ testing and manufacturing.
Each of the 50 million Americans will receive two doses.
The deal will cost around $42 per person inoculated.
Sanofi and GlaxoSmithKline would conduct clinical trials for the vaccine in September.
The US government has the option to purchase an additional 500 million doses at an unspecified price.
Sanofi executive Clement Lewin said the companies have yet to agree with the government on the price for the additional doses.
According to Alex Azar, secretary of the US Department of Health and Human Services, the product being developed by Sanofi and GSK has the potential to bring hundreds of millions of safe and effective doses.
The award is so far the biggest from the White House initiative to accelerate access to vaccines and treatments to fight COVID-19 dubbed ‘Operation Warp Speed.’
Last week, the US agreed to pay Pfizer Inc and BioNTech SE $2 billion deal for 50 million courses of the potential vaccine.
The price per patient is $40.
The coronavirus has infected 4.5 million Americans and killed over 152,000 Americans.
The US Centers for Disease Control forecasts between 168,000 and 182,000 total fatalities by August 22.
The deaths will supposedly rise fastest in Alabama, Tennessee, Washington state, Kentucky, New Jersey, and Puerto Rico.
